1
|
Berman DM, Lee AY, Lesurf R, Patel PG, Ebrahimizadeh W, Bayani J, Lee LA, Boufaied N, Selvarajah S, Jamaspishvili T, Guérard KP, Dion D, Kawashima A, Clarke GM, How N, Jackson CL, Scarlata E, Siddiqui K, Okello JBA, Aprikian AG, Moussa M, Finelli A, Chin J, Brimo F, Bauman G, Loblaw A, Venkateswaran V, Buttyan R, Chevalier S, Thomson A, Park PC, Siemens DR, Lapointe J, Boutros PC, Bartlett JMS. Multimodal Biomarkers That Predict the Presence of Gleason Pattern 4: Potential Impact for Active Surveillance. J Urol 2023; 210:257-271. [PMID: 37126232 DOI: 10.1097/ju.0000000000003507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2022] [Accepted: 04/20/2023] [Indexed: 05/02/2023]
Abstract
PURPOSE Latent grade group ≥2 prostate cancer can impact the performance of active surveillance protocols. To date, molecular biomarkers for active surveillance have relied solely on RNA or protein. We trained and independently validated multimodal (mRNA abundance, DNA methylation, and/or DNA copy number) biomarkers that more accurately separate grade group 1 from grade group ≥2 cancers. MATERIALS AND METHODS Low- and intermediate-risk prostate cancer patients were assigned to training (n=333) and validation (n=202) cohorts. We profiled the abundance of 342 mRNAs, 100 DNA copy number alteration loci, and 14 hypermethylation sites at 2 locations per tumor. Using the training cohort with cross-validation, we evaluated methods for training classifiers of pathological grade group ≥2 in centrally reviewed radical prostatectomies. We trained 2 distinct classifiers, PRONTO-e and PRONTO-m, and validated them in an independent radical prostatectomy cohort. RESULTS PRONTO-e comprises 353 mRNA and copy number alteration features. PRONTO-m includes 94 clinical, mRNAs, copy number alterations, and methylation features at 14 and 12 loci, respectively. In independent validation, PRONTO-e and PRONTO-m predicted grade group ≥2 with respective true-positive rates of 0.81 and 0.76, and false-positive rates of 0.43 and 0.26. Both classifiers were resistant to sampling error and identified more upgrading cases than a well-validated presurgical risk calculator, CAPRA (Cancer of the Prostate Risk Assessment; P < .001). CONCLUSIONS Two grade group classifiers with superior accuracy were developed by incorporating RNA and DNA features and validated in an independent cohort. Upon further validation in biopsy samples, classifiers with these performance characteristics could refine selection of men for active surveillance, extending their treatment-free survival and intervals between surveillance.
Collapse
Affiliation(s)
- D M Berman
- Queen's University Cancer Research Institute, Kingston, Ontario, Canada
- Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada
| | - A Y Lee
- Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - R Lesurf
- Ontario Institute for Cancer Research, Toronto, Ontario, Canada
- Now with Hospital for Sick Children, Toronto, Ontario, Canada
| | - P G Patel
- Queen's University Cancer Research Institute, Kingston, Ontario, Canada
- Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada
- Now with Hospital for Sick Children, Toronto, Ontario, Canada
| | - W Ebrahimizadeh
- Department of Surgery, McGill University and the Research Institute of the McGill University Health Centre, Montréal, Québec, Canada
- Now with IMV Inc, Dartmouth, Nova Scotia, Canada
| | - J Bayani
- Ontario Institute for Cancer Research, Toronto, Ontario, Canada
- Department of Laboratory Medicine and Pathology, University of Toronto, Toronto, Ontario, Canada
| | - L A Lee
- Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - N Boufaied
- Department of Surgery, McGill University and the Research Institute of the McGill University Health Centre, Montréal, Québec, Canada
| | - S Selvarajah
- Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada
- Now with University Health Network, Toronto, Ontario, Canada
| | - T Jamaspishvili
- Queen's University Cancer Research Institute, Kingston, Ontario, Canada
- Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada
| | - K-P Guérard
- Department of Surgery, McGill University and the Research Institute of the McGill University Health Centre, Montréal, Québec, Canada
| | - D Dion
- Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - A Kawashima
- Queen's University Cancer Research Institute, Kingston, Ontario, Canada
- Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada
- Now with Osaka University, Osaka, Japan
| | - G M Clarke
- Ontario Institute for Cancer Research, Toronto, Ontario, Canada
| | - N How
- Queen's University Cancer Research Institute, Kingston, Ontario, Canada
- Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada
- Hamilton Health Sciences, Hamilton, Ontario, Canada
| | - C L Jackson
- Queen's University Cancer Research Institute, Kingston, Ontario, Canada
- Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada
| | - E Scarlata
- Department of Surgery, McGill University and the Research Institute of the McGill University Health Centre, Montréal, Québec, Canada
| | - K Siddiqui
- Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada
- Now with Sultan Qaboos University Hospital, Seeb, Oman
| | - J B A Okello
- Queen's University Cancer Research Institute, Kingston, Ontario, Canada
- Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada
| | - A G Aprikian
- Department of Surgery, McGill University and the Research Institute of the McGill University Health Centre, Montréal, Québec, Canada
| | - M Moussa
- Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada
- London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada
| | - A Finelli
- Princess Margaret Cancer Centre. Toronto, Ontario, Canada
- Departments of Surgery and Oncology, University of Toronto, Toronto, Ontario, Canada
| | - J Chin
- Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada
- London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada
| | - F Brimo
- Department of Surgery, McGill University and the Research Institute of the McGill University Health Centre, Montréal, Québec, Canada
- Department of Pathology, McGill University, Montreal, Quebec, Canada
| | - G Bauman
- Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada
- London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada
| | - A Loblaw
- Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- Departments of Radiation Oncology and Health Policy Management and Evaluation, University of Toronto, Toronto
| | - V Venkateswaran
- Departments of Surgery and Oncology, University of Toronto, Toronto, Ontario, Canada
- Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
| | - R Buttyan
- Vancouver Prostate Centre, Vancouver, British Columbia, Canada
- Departments of Experimental Medicine and Interdisciplinary Oncology, Vancouver, British Columbia, Canada
| | - S Chevalier
- Department of Surgery, McGill University and the Research Institute of the McGill University Health Centre, Montréal, Québec, Canada
| | - A Thomson
- Department of Surgery, McGill University and the Research Institute of the McGill University Health Centre, Montréal, Québec, Canada
- Now with College of Science and Engineering Biology, University of Edinburgh, Edinburgh, United Kingdom
| | - P C Park
- Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada
- Now with Department of Pathology, Shared Health, Winnipeg, Manitoba, Canada
| | - D R Siemens
- Queen's University Cancer Research Institute, Kingston, Ontario, Canada
- Departments of Urology, Oncology and Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada
| | - J Lapointe
- Department of Surgery, McGill University and the Research Institute of the McGill University Health Centre, Montréal, Québec, Canada
| | - P C Boutros
- Ontario Institute for Cancer Research, Toronto, Ontario, Canada
- Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada
- Now with University of California, Los Angeles, Los Angeles, California, United States
| | - J M S Bartlett
- Ontario Institute for Cancer Research, Toronto, Ontario, Canada
- Department of Laboratory Medicine and Pathology, University of Toronto, Toronto, Ontario, Canada
- Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, United Kingdom
| |
Collapse
|
2
|
Lee YC, Lee LA, Chao WC, Luo CM, Lee YH, Yang SW. Use of an autologous bony crossbar graft for the management of caudal septal deviation: Our experience in twenty-two patients. Clin Otolaryngol 2018; 43:1125-1129. [PMID: 29443451 DOI: 10.1111/coa.13081] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/06/2018] [Indexed: 11/29/2022]
Affiliation(s)
- Y-C Lee
- Department of Otolaryngology - Head and Neck Surgery, Chang Gung Memorial Hospital, Keelung, Taiwan.,College of Medicine, Chang Gung University, Tao-Yuan, Taiwan
| | - L-A Lee
- College of Medicine, Chang Gung University, Tao-Yuan, Taiwan.,Department of Otolaryngology - Head and Neck Surgery, Chang Gung Memorial Hospital, Tao-Yuan, Taiwan
| | - W-C Chao
- Department of Otolaryngology - Head and Neck Surgery, Chang Gung Memorial Hospital, Keelung, Taiwan.,College of Medicine, Chang Gung University, Tao-Yuan, Taiwan
| | - C-M Luo
- Department of Otolaryngology - Head and Neck Surgery, Chang Gung Memorial Hospital, Keelung, Taiwan
| | - Y-H Lee
- Department of Orthopedic Surgery, Buddhist Tzu-Chi General Hospital, Taipei, Taiwan
| | - S-W Yang
- Department of Otolaryngology - Head and Neck Surgery, Chang Gung Memorial Hospital, Keelung, Taiwan.,College of Medicine, Chang Gung University, Tao-Yuan, Taiwan
| |
Collapse
|
3
|
Hasler WL, May KP, Wilson LA, Van Natta M, Parkman HP, Pasricha PJ, Koch KL, Abell TL, McCallum RW, Nguyen LA, Snape WJ, Sarosiek I, Clarke JO, Farrugia G, Calles-Escandon J, Grover M, Tonascia J, Lee LA, Miriel L, Hamilton FA. Relating gastric scintigraphy and symptoms to motility capsule transit and pressure findings in suspected gastroparesis. Neurogastroenterol Motil 2018; 30:10.1111/nmo.13196. [PMID: 28872760 PMCID: PMC6004323 DOI: 10.1111/nmo.13196] [Citation(s) in RCA: 51] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/06/2017] [Accepted: 07/25/2017] [Indexed: 12/13/2022]
Abstract
BACKGROUND Wireless motility capsule (WMC) findings are incompletely defined in suspected gastroparesis. We aimed to characterize regional WMC transit and contractility in relation to scintigraphy, etiology, and symptoms in patients undergoing gastric emptying testing. METHODS A total of 209 patients with gastroparesis symptoms at NIDDK Gastroparesis Consortium centers underwent gastric scintigraphy and WMCs on separate days to measure regional transit and contractility. Validated questionnaires quantified symptoms. KEY RESULTS Solid scintigraphy and liquid scintigraphy were delayed in 68.8% and 34.8% of patients; WMC gastric emptying times (GET) were delayed in 40.3% and showed 52.8% agreement with scintigraphy; 15.5% and 33.5% had delayed small bowel (SBTT) and colon transit (CTT) times. Transit was delayed in ≥2 regions in 23.3%. Rapid transit was rarely observed. Diabetics had slower GET but more rapid SBTT versus idiopathics (P ≤ .02). GET delays related to greater scintigraphic retention, slower SBTT, and fewer gastric contractions (P ≤ .04). Overall gastroparesis symptoms and nausea/vomiting, early satiety/fullness, bloating/distention, and upper abdominal pain subscores showed no relation to WMC transit. Upper and lower abdominal pain scores (P ≤ .03) were greater with increased colon contractions. Constipation correlated with slower CTT and higher colon contractions (P = .03). Diarrhea scores were higher with delayed SBTT and CTT (P ≤ .04). CONCLUSIONS & INFERENCES Wireless motility capsules define gastric emptying delays similar but not identical to scintigraphy that are more severe in diabetics and relate to reduced gastric contractility. Extragastric transit delays occur in >40% with suspected gastroparesis. Gastroparesis symptoms show little association with WMC profiles, although lower symptoms relate to small bowel or colon abnormalities.
Collapse
Affiliation(s)
- W L Hasler
- Division of Gastroenterology, University of Michigan, Ann Arbor, MI, USA
| | - K P May
- Data Coordinating Center, Johns Hopkins University, Baltimore, MD, USA
| | - L A Wilson
- Data Coordinating Center, Johns Hopkins University, Baltimore, MD, USA
| | - M Van Natta
- Data Coordinating Center, Johns Hopkins University, Baltimore, MD, USA
| | - H P Parkman
- Section of Gastroenterology, Temple University, Philadelphia, PA, USA
| | - P J Pasricha
- Section of Gastroenterology, Johns Hopkins University, Baltimore, MD, USA
| | - K L Koch
- Section on Gastroenterology, Wake Forest University, Winston Salem, NC, USA
| | - T L Abell
- Division of Gastroenterology, University of Louisville, Louisville, KY, USA
| | - R W McCallum
- Section of Gastroenterology, Texas Tech University, El Paso, TX, USA
| | - L A Nguyen
- Division of Gastroenterology, Stanford University, Palo Alto, CA, USA
| | - W J Snape
- Division of Gastroenterology, California Pacific Medical Center, San Francisco, CA, USA
| | - I Sarosiek
- Section of Gastroenterology, Texas Tech University, El Paso, TX, USA
| | - J O Clarke
- Division of Gastroenterology, Stanford University, Palo Alto, CA, USA
| | - G Farrugia
- Section of Gastroenterology, Mayo Clinic, Rochester, MN, USA
| | - J Calles-Escandon
- Endocrinology Section, MetroHealth Medical Center, Cleveland, OH, USA
| | - M Grover
- Section of Gastroenterology, Mayo Clinic, Rochester, MN, USA
| | - J Tonascia
- Data Coordinating Center, Johns Hopkins University, Baltimore, MD, USA
| | - L A Lee
- Section of Gastroenterology, Johns Hopkins University Data Coordinating Center, Baltimore, MD, USA
| | - L Miriel
- Data Coordinating Center, Johns Hopkins University, Baltimore, MD, USA
| | - F A Hamilton
- National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA
| |
Collapse
|
4
|
Ellis AK, Tsitoura DC, Quint D, Powley W, Lee LA. Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: A randomized trial. Clin Exp Allergy 2017; 47:1193-1203. [PMID: 28681506 DOI: 10.1111/cea.12974] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2016] [Revised: 05/04/2017] [Accepted: 05/10/2017] [Indexed: 12/21/2022]
Abstract
BACKGROUND Toll-like receptor 7 (TLR7) stimulation in the airways may reduce responses to aeroallergens by induction of type 1 interferons (IFNs). GSK2245035 is a novel selective TLR7 agonist in pharmaceutical development. OBJECTIVE Assessment of safety, pharmacodynamics and nasal allergic reactivity following repeated weekly intranasal (i.n.) GSK2245035. METHODS This randomized, double-blind, placebo-controlled study (TL7116958) was conducted over two pollen seasons (2013-2014) and follow-up study (204509) conducted 1 year later. Participants with allergic rhinitis (n=42) were randomized to receive eight weekly doses of i.n. GSK2245035 (20 ng [2014 Cohort; n=14] or 80 ng [2013 Cohort; n=14]) or placebo (n=14). Adverse events (AEs) including cytokine release syndrome AEs (CytoRS-AEs) and nasal symptoms were assessed. Nasal and serum IFN-inducible protein 10 (IP-10) were measured after doses 1 and 8, then 1 (follow-up visit [FUV] 1) and 3 (FUV2) weeks after final dose. Nasal allergen challenges (NACs) and allergic biomarker assessment (nasal, serum) were conducted at baseline, FUV1, FUV2 and at a FUV 1 year after final dose (FUV3; 2014 Cohort only). A Bayesian framework enabled probability statements for mean effect sizes. RESULTS GSK2245035 induced CytoRS-AEs (most commonly headache, median duration <1 day) in 93% of participants at 80 ng, while AE incidence at 20 ng was similar to placebo. There was no evidence of nasal inflammation. Dose-related increases in nasal and serum IP-10 were observed 24 hours after doses 1 and 8 (>95% certainty). Both doses showed a trend in reducing total nasal symptom score 15 minutes post-NAC at FUV1 and FUV2, but there was no reduction evident at FUV3. Nasal levels of selected allergic biomarkers demonstrated trends for reductions at FUV1, FUV2 and FUV3. CONCLUSIONS AND CLINICAL RELEVANCE Weekly i.n. GSK2245035 20 ng was well tolerated and reduced allergic reactivity to nasal challenge for 3 weeks post-treatment.
Collapse
Affiliation(s)
- A K Ellis
- Department of Medicine, Queen's University, Kingston, Ontario, Canada
| | | | - D Quint
- GlaxoSmithKline, Stevenage, Hertfordshire, UK
| | - W Powley
- GlaxoSmithKline, Stevenage, Hertfordshire, UK
| | - L A Lee
- GlaxoSmithKline, Stevenage, Hertfordshire, UK
| |
Collapse
|
5
|
Pomeroy EJ, Lee LA, Lee RDW, Schirm DK, Temiz NA, Ma J, Gruber TA, Diaz-Flores E, Moriarity BS, Downing JR, Shannon KM, Largaespada DA, Eckfeldt CE. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia. Oncogene 2016; 36:3263-3273. [PMID: 27991934 PMCID: PMC5464975 DOI: 10.1038/onc.2016.471] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2016] [Revised: 10/17/2016] [Accepted: 11/07/2016] [Indexed: 12/22/2022]
Abstract
Somatic mutations that lead to constitutive activation of NRAS and KRAS proto-oncogenes are among the most common in human cancer and frequently occur in acute myeloid leukemia (AML). An inducible NRAS(V12)-driven AML mouse model has established a critical role for continued NRAS(V12) expression in leukemia maintenance. In this model genetic suppression of NRAS(V12) expression results in rapid leukemia remission, but some mice undergo spontaneous relapse with NRAS(V12)-independent (NRI) AMLs providing an opportunity to identify mechanisms that bypass the requirement for Ras oncogene activity and drive leukemia relapse. We found that relapsed NRI AMLs are devoid of NRAS(V12) expression and signaling through the major oncogenic Ras effector pathways, phosphatidylinositol-3-kinase and mitogen-activated protein kinase, but express higher levels of an alternate Ras effector, Ralb, and exhibit NRI phosphorylation of the RALB effector TBK1, implicating RALB signaling in AML relapse. Functional studies confirmed that inhibiting CDK5-mediated RALB activation with a clinically relevant experimental drug, dinaciclib, led to potent RALB-dependent antileukemic effects in human AML cell lines, induced apoptosis in patient-derived AML samples in vitro and led to a 2-log reduction in the leukemic burden in patient-derived xenograft mice. Furthermore, dinaciclib potently suppressed the clonogenic potential of relapsed NRI AMLs in vitro and prevented the development of relapsed AML in vivo. Our findings demonstrate that Ras oncogene-independent activation of RALB signaling is a therapeutically targetable mechanism of escape from NRAS oncogene addiction in AML.
Collapse
Affiliation(s)
- E J Pomeroy
- Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, University of Minnesota, Minneapolis, MN, USA
| | - L A Lee
- Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, University of Minnesota, Minneapolis, MN, USA
| | - R D W Lee
- Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, University of Minnesota, Minneapolis, MN, USA
| | - D K Schirm
- Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, University of Minnesota, Minneapolis, MN, USA
| | - N A Temiz
- Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA
| | - J Ma
- Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - T A Gruber
- Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA.,Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - E Diaz-Flores
- Department of Pediatrics, University of California, San Francisco, CA, USA
| | - B S Moriarity
- Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.,Department of Pediatrics, Division of Hematology and Oncology, Minneapolis, MN, USA
| | - J R Downing
- Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA
| | - K M Shannon
- Department of Pediatrics, University of California, San Francisco, CA, USA
| | - D A Largaespada
- Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.,Department of Pediatrics, Division of Hematology and Oncology, Minneapolis, MN, USA.,Department of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, MN, USA
| | - C E Eckfeldt
- Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, University of Minnesota, Minneapolis, MN, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA
| |
Collapse
|
6
|
Whitworth P, Beitsch P, Baron P, Beatty J, Pellicane JV, Murray MK, Dul CL, Mislowsky AM, Nash CH, Richards PD, Lee LA, Stork-Sloots L, de Snoo F, Untch S, Gittleman M, Akbari S, Rotkis MC. Abstract P1-14-05: Three distinct HER2 subtypes identified by BluePrint 80-gene functional subtyping predict treatment-specific response in the prospective neo-adjuvant NBRST registry. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-14-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Ideally classification by subtype predicts treatment response and overall outcome. BluePrint 80-gene functional molecular subtype is based on mRNA expression (as is intrinsic subtype) associated with intact translation to protein (unlike intrinsic subtype). BluePrint (BP) classifies patients into Luminal, Her2 or Basal-type. Presently subtype is approximated using conventional immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) ("conventional subtype") or assigned by gene expression profiling. The main objective of the prospective neo-adjuvant NBRST study is to compare drug sensitivity as defined by pathological Complete Response (pCR), using 80-gene functional subtype vs. conventional IHC/FISH subtyping. NBRST enrolled over 1,000 US patients between June 2011 and December 2014. In this analysis we present the results for IHC/FISH Her2-positive patients.
Methods
Here we report findings in the 260 NBRST patients who had IHC/FISH Her2+ breast cancer, according to ASCO CAP guidelines at the time of diagnosis. Treatment, including chemotherapy and HER2-targeted agents, was at the discretion of the physician adhering to NCCN approved or other peer-reviewed, established regimens over the course of the study. pCR was defined as T0/isN0. Fisher's exact test was used to compare pCR rates among IHC/FISH and functional subtypes and treatment groups.
Results
The 260 IHC/FISH Her2+ patients had median age 53 (range 23-81) and included T1-4, N0-3 tumors. Of 169 ER+/Her2+ tumors 49% were re-classified as BP Luminal, 43% as BP HER2, and 8% as BP Basal. The median ER% of ER+/Her2+/BP Luminal tumors was 93% (range 3-100), compared to 79% in ER+/Her2+/BP HER2 (range 1-91) and 8% in ER+/Her2+/BP Basal-type (range 2-99).The overall pCR rate in ER+/Her2+/BP Luminal was 17% (4% with chemo/trastuzumab; 39% chemo/trastuzumab/pertuzumab, p<0.0001) and statistically inferior (p<0.0001) to the 59% pCR rate in ER+/Her2+/BP HER2. Of 91 ER-/Her2+ tumors 74% were classified as BP HER2, 25% were re-classified BP Basal and <1% was BP Luminal. NCT pCR rates for ER-/Her2+/BP HER2 was 67% (64% with chemo/trastuzumab; 77% chemo/trastuzumab/pertuzumab, p=0.40) and significantly superior (p=0.026) to the 39% pCR rate in ER-/Her2+/BP Basal (p=0.026).
Conclusions
In the NBRST study, BP 80-gene functional subtype (based on mRNA expression and translation): 1. Re-classifies over half of all IHC/FISH ER+/Her2+ patients; 2. Predicts treatment response or resistance in Her2+ patients not segregated by conventional IHC/FISH classification and 3. Identifies ER+/Her2+ tumors that are sensitive to chemo/trastuzumab/pertuzumab but resistant to chemo/trastuzumab.
Citation Format: Whitworth P, Beitsch P, Baron P, Beatty J, Pellicane JV, Murray MK, Dul CL, Mislowsky AM, Nash CH, Richards PD, Lee LA, Stork-Sloots L, de Snoo F, Untch S, Gittleman M, Akbari S, Rotkis MC. Three distinct HER2 subtypes identified by BluePrint 80-gene functional subtyping predict treatment-specific response in the prospective neo-adjuvant NBRST registry. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-14-05.
Collapse
Affiliation(s)
- P Whitworth
- Nashville Breast Center, Nashville, TN; Dallas Surgical Group, Dallas, TX; Breast & Melanoma Specialists of Charleston, Charleston, SC; The Breast Place, Charleston, SC; Virginia Breast Center, Bon Secours Cancer Institute, Richmond, VA; Akron General Hospita, Akron, OH; St. John Hospital & Medical Center, Detroit, MI; Coastal Carolina Breast Center, Murrells Inlet, SC; Northeast Georgia Medical Center, Gainesville GA, Gainesville, GA; Blue Ridge Cancer Care, Roanoke, VA; Comprehensive Cancer Center, Palm Springs, CA; Agendia Inc, Irvine, CA; Breast Care Specialists, Allentown, PA; Virginia Hospital Center, Arlington, VA; Northern Indiana Cancer Research Consortium, South Bend, IN
| | - P Beitsch
- Nashville Breast Center, Nashville, TN; Dallas Surgical Group, Dallas, TX; Breast & Melanoma Specialists of Charleston, Charleston, SC; The Breast Place, Charleston, SC; Virginia Breast Center, Bon Secours Cancer Institute, Richmond, VA; Akron General Hospita, Akron, OH; St. John Hospital & Medical Center, Detroit, MI; Coastal Carolina Breast Center, Murrells Inlet, SC; Northeast Georgia Medical Center, Gainesville GA, Gainesville, GA; Blue Ridge Cancer Care, Roanoke, VA; Comprehensive Cancer Center, Palm Springs, CA; Agendia Inc, Irvine, CA; Breast Care Specialists, Allentown, PA; Virginia Hospital Center, Arlington, VA; Northern Indiana Cancer Research Consortium, South Bend, IN
| | - P Baron
- Nashville Breast Center, Nashville, TN; Dallas Surgical Group, Dallas, TX; Breast & Melanoma Specialists of Charleston, Charleston, SC; The Breast Place, Charleston, SC; Virginia Breast Center, Bon Secours Cancer Institute, Richmond, VA; Akron General Hospita, Akron, OH; St. John Hospital & Medical Center, Detroit, MI; Coastal Carolina Breast Center, Murrells Inlet, SC; Northeast Georgia Medical Center, Gainesville GA, Gainesville, GA; Blue Ridge Cancer Care, Roanoke, VA; Comprehensive Cancer Center, Palm Springs, CA; Agendia Inc, Irvine, CA; Breast Care Specialists, Allentown, PA; Virginia Hospital Center, Arlington, VA; Northern Indiana Cancer Research Consortium, South Bend, IN
| | - J Beatty
- Nashville Breast Center, Nashville, TN; Dallas Surgical Group, Dallas, TX; Breast & Melanoma Specialists of Charleston, Charleston, SC; The Breast Place, Charleston, SC; Virginia Breast Center, Bon Secours Cancer Institute, Richmond, VA; Akron General Hospita, Akron, OH; St. John Hospital & Medical Center, Detroit, MI; Coastal Carolina Breast Center, Murrells Inlet, SC; Northeast Georgia Medical Center, Gainesville GA, Gainesville, GA; Blue Ridge Cancer Care, Roanoke, VA; Comprehensive Cancer Center, Palm Springs, CA; Agendia Inc, Irvine, CA; Breast Care Specialists, Allentown, PA; Virginia Hospital Center, Arlington, VA; Northern Indiana Cancer Research Consortium, South Bend, IN
| | - JV Pellicane
- Nashville Breast Center, Nashville, TN; Dallas Surgical Group, Dallas, TX; Breast & Melanoma Specialists of Charleston, Charleston, SC; The Breast Place, Charleston, SC; Virginia Breast Center, Bon Secours Cancer Institute, Richmond, VA; Akron General Hospita, Akron, OH; St. John Hospital & Medical Center, Detroit, MI; Coastal Carolina Breast Center, Murrells Inlet, SC; Northeast Georgia Medical Center, Gainesville GA, Gainesville, GA; Blue Ridge Cancer Care, Roanoke, VA; Comprehensive Cancer Center, Palm Springs, CA; Agendia Inc, Irvine, CA; Breast Care Specialists, Allentown, PA; Virginia Hospital Center, Arlington, VA; Northern Indiana Cancer Research Consortium, South Bend, IN
| | - MK Murray
- Nashville Breast Center, Nashville, TN; Dallas Surgical Group, Dallas, TX; Breast & Melanoma Specialists of Charleston, Charleston, SC; The Breast Place, Charleston, SC; Virginia Breast Center, Bon Secours Cancer Institute, Richmond, VA; Akron General Hospita, Akron, OH; St. John Hospital & Medical Center, Detroit, MI; Coastal Carolina Breast Center, Murrells Inlet, SC; Northeast Georgia Medical Center, Gainesville GA, Gainesville, GA; Blue Ridge Cancer Care, Roanoke, VA; Comprehensive Cancer Center, Palm Springs, CA; Agendia Inc, Irvine, CA; Breast Care Specialists, Allentown, PA; Virginia Hospital Center, Arlington, VA; Northern Indiana Cancer Research Consortium, South Bend, IN
| | - CL Dul
- Nashville Breast Center, Nashville, TN; Dallas Surgical Group, Dallas, TX; Breast & Melanoma Specialists of Charleston, Charleston, SC; The Breast Place, Charleston, SC; Virginia Breast Center, Bon Secours Cancer Institute, Richmond, VA; Akron General Hospita, Akron, OH; St. John Hospital & Medical Center, Detroit, MI; Coastal Carolina Breast Center, Murrells Inlet, SC; Northeast Georgia Medical Center, Gainesville GA, Gainesville, GA; Blue Ridge Cancer Care, Roanoke, VA; Comprehensive Cancer Center, Palm Springs, CA; Agendia Inc, Irvine, CA; Breast Care Specialists, Allentown, PA; Virginia Hospital Center, Arlington, VA; Northern Indiana Cancer Research Consortium, South Bend, IN
| | - AM Mislowsky
- Nashville Breast Center, Nashville, TN; Dallas Surgical Group, Dallas, TX; Breast & Melanoma Specialists of Charleston, Charleston, SC; The Breast Place, Charleston, SC; Virginia Breast Center, Bon Secours Cancer Institute, Richmond, VA; Akron General Hospita, Akron, OH; St. John Hospital & Medical Center, Detroit, MI; Coastal Carolina Breast Center, Murrells Inlet, SC; Northeast Georgia Medical Center, Gainesville GA, Gainesville, GA; Blue Ridge Cancer Care, Roanoke, VA; Comprehensive Cancer Center, Palm Springs, CA; Agendia Inc, Irvine, CA; Breast Care Specialists, Allentown, PA; Virginia Hospital Center, Arlington, VA; Northern Indiana Cancer Research Consortium, South Bend, IN
| | - CH Nash
- Nashville Breast Center, Nashville, TN; Dallas Surgical Group, Dallas, TX; Breast & Melanoma Specialists of Charleston, Charleston, SC; The Breast Place, Charleston, SC; Virginia Breast Center, Bon Secours Cancer Institute, Richmond, VA; Akron General Hospita, Akron, OH; St. John Hospital & Medical Center, Detroit, MI; Coastal Carolina Breast Center, Murrells Inlet, SC; Northeast Georgia Medical Center, Gainesville GA, Gainesville, GA; Blue Ridge Cancer Care, Roanoke, VA; Comprehensive Cancer Center, Palm Springs, CA; Agendia Inc, Irvine, CA; Breast Care Specialists, Allentown, PA; Virginia Hospital Center, Arlington, VA; Northern Indiana Cancer Research Consortium, South Bend, IN
| | - PD Richards
- Nashville Breast Center, Nashville, TN; Dallas Surgical Group, Dallas, TX; Breast & Melanoma Specialists of Charleston, Charleston, SC; The Breast Place, Charleston, SC; Virginia Breast Center, Bon Secours Cancer Institute, Richmond, VA; Akron General Hospita, Akron, OH; St. John Hospital & Medical Center, Detroit, MI; Coastal Carolina Breast Center, Murrells Inlet, SC; Northeast Georgia Medical Center, Gainesville GA, Gainesville, GA; Blue Ridge Cancer Care, Roanoke, VA; Comprehensive Cancer Center, Palm Springs, CA; Agendia Inc, Irvine, CA; Breast Care Specialists, Allentown, PA; Virginia Hospital Center, Arlington, VA; Northern Indiana Cancer Research Consortium, South Bend, IN
| | - LA Lee
- Nashville Breast Center, Nashville, TN; Dallas Surgical Group, Dallas, TX; Breast & Melanoma Specialists of Charleston, Charleston, SC; The Breast Place, Charleston, SC; Virginia Breast Center, Bon Secours Cancer Institute, Richmond, VA; Akron General Hospita, Akron, OH; St. John Hospital & Medical Center, Detroit, MI; Coastal Carolina Breast Center, Murrells Inlet, SC; Northeast Georgia Medical Center, Gainesville GA, Gainesville, GA; Blue Ridge Cancer Care, Roanoke, VA; Comprehensive Cancer Center, Palm Springs, CA; Agendia Inc, Irvine, CA; Breast Care Specialists, Allentown, PA; Virginia Hospital Center, Arlington, VA; Northern Indiana Cancer Research Consortium, South Bend, IN
| | - L Stork-Sloots
- Nashville Breast Center, Nashville, TN; Dallas Surgical Group, Dallas, TX; Breast & Melanoma Specialists of Charleston, Charleston, SC; The Breast Place, Charleston, SC; Virginia Breast Center, Bon Secours Cancer Institute, Richmond, VA; Akron General Hospita, Akron, OH; St. John Hospital & Medical Center, Detroit, MI; Coastal Carolina Breast Center, Murrells Inlet, SC; Northeast Georgia Medical Center, Gainesville GA, Gainesville, GA; Blue Ridge Cancer Care, Roanoke, VA; Comprehensive Cancer Center, Palm Springs, CA; Agendia Inc, Irvine, CA; Breast Care Specialists, Allentown, PA; Virginia Hospital Center, Arlington, VA; Northern Indiana Cancer Research Consortium, South Bend, IN
| | - F de Snoo
- Nashville Breast Center, Nashville, TN; Dallas Surgical Group, Dallas, TX; Breast & Melanoma Specialists of Charleston, Charleston, SC; The Breast Place, Charleston, SC; Virginia Breast Center, Bon Secours Cancer Institute, Richmond, VA; Akron General Hospita, Akron, OH; St. John Hospital & Medical Center, Detroit, MI; Coastal Carolina Breast Center, Murrells Inlet, SC; Northeast Georgia Medical Center, Gainesville GA, Gainesville, GA; Blue Ridge Cancer Care, Roanoke, VA; Comprehensive Cancer Center, Palm Springs, CA; Agendia Inc, Irvine, CA; Breast Care Specialists, Allentown, PA; Virginia Hospital Center, Arlington, VA; Northern Indiana Cancer Research Consortium, South Bend, IN
| | - S Untch
- Nashville Breast Center, Nashville, TN; Dallas Surgical Group, Dallas, TX; Breast & Melanoma Specialists of Charleston, Charleston, SC; The Breast Place, Charleston, SC; Virginia Breast Center, Bon Secours Cancer Institute, Richmond, VA; Akron General Hospita, Akron, OH; St. John Hospital & Medical Center, Detroit, MI; Coastal Carolina Breast Center, Murrells Inlet, SC; Northeast Georgia Medical Center, Gainesville GA, Gainesville, GA; Blue Ridge Cancer Care, Roanoke, VA; Comprehensive Cancer Center, Palm Springs, CA; Agendia Inc, Irvine, CA; Breast Care Specialists, Allentown, PA; Virginia Hospital Center, Arlington, VA; Northern Indiana Cancer Research Consortium, South Bend, IN
| | - M Gittleman
- Nashville Breast Center, Nashville, TN; Dallas Surgical Group, Dallas, TX; Breast & Melanoma Specialists of Charleston, Charleston, SC; The Breast Place, Charleston, SC; Virginia Breast Center, Bon Secours Cancer Institute, Richmond, VA; Akron General Hospita, Akron, OH; St. John Hospital & Medical Center, Detroit, MI; Coastal Carolina Breast Center, Murrells Inlet, SC; Northeast Georgia Medical Center, Gainesville GA, Gainesville, GA; Blue Ridge Cancer Care, Roanoke, VA; Comprehensive Cancer Center, Palm Springs, CA; Agendia Inc, Irvine, CA; Breast Care Specialists, Allentown, PA; Virginia Hospital Center, Arlington, VA; Northern Indiana Cancer Research Consortium, South Bend, IN
| | - S Akbari
- Nashville Breast Center, Nashville, TN; Dallas Surgical Group, Dallas, TX; Breast & Melanoma Specialists of Charleston, Charleston, SC; The Breast Place, Charleston, SC; Virginia Breast Center, Bon Secours Cancer Institute, Richmond, VA; Akron General Hospita, Akron, OH; St. John Hospital & Medical Center, Detroit, MI; Coastal Carolina Breast Center, Murrells Inlet, SC; Northeast Georgia Medical Center, Gainesville GA, Gainesville, GA; Blue Ridge Cancer Care, Roanoke, VA; Comprehensive Cancer Center, Palm Springs, CA; Agendia Inc, Irvine, CA; Breast Care Specialists, Allentown, PA; Virginia Hospital Center, Arlington, VA; Northern Indiana Cancer Research Consortium, South Bend, IN
| | - MC Rotkis
- Nashville Breast Center, Nashville, TN; Dallas Surgical Group, Dallas, TX; Breast & Melanoma Specialists of Charleston, Charleston, SC; The Breast Place, Charleston, SC; Virginia Breast Center, Bon Secours Cancer Institute, Richmond, VA; Akron General Hospita, Akron, OH; St. John Hospital & Medical Center, Detroit, MI; Coastal Carolina Breast Center, Murrells Inlet, SC; Northeast Georgia Medical Center, Gainesville GA, Gainesville, GA; Blue Ridge Cancer Care, Roanoke, VA; Comprehensive Cancer Center, Palm Springs, CA; Agendia Inc, Irvine, CA; Breast Care Specialists, Allentown, PA; Virginia Hospital Center, Arlington, VA; Northern Indiana Cancer Research Consortium, South Bend, IN
| |
Collapse
|
7
|
Beitsch P, Whitworth P, Baron P, Beatty J, Pellicane JV, Murray MK, Dul C, Mislowsky AM, Nash CH, Richards PD, Lee LA, Stork-Sloots L, de Snoo F, Untch S, Gittleman M, Akbari S, Rotkis MC. Abstract P4-14-29: One-third of HER2 positive patients have 80-gene luminal subtype that is resistant to chemo-trastuzumab but sensitive to chemo-trastuzumab-pertuzumab: Critical implications for the adjuvant setting from the NBRST phase 4 neoadjuvant study. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-14-29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
The phase 4 Neo-adjuvant Breast Registry Symphony Trial (NBRST) enrolled over 1,000 US patients between June 2011 and December 2014. The aim of NBRST study is to compare chemo-sensitivity as defined by pathological Complete Response (pCR) using the 80-gene BluePrint (BP) functional subtype profile vs. conventional IHC/FISH subtyping. Treatment was at the discretion of the physician utilizing standard NCCN regimens. Pertuzumab, a monoclonal antibody, inhibits the dimerization of HER2 with other HER receptors. Pertuzumab received US FDA approval for the neo-adjuvant treatment of HER2-positive breast cancer in September 2013. Essentially all patients with HER2 positive cancers were treated with chemotherapy + trastuzumab and after this date pertuzumab was added, creating 2 distinct groups of Her2-treated patients.
The aim of the current analysis is to compare the pCR rate of chemo-trastuzumab (c-t) vs chemo-trastuzumab plus pertuzumab (c-t-p) by conventional and 80-gene BP functional subtype. 80-gene BP functional subtype was derived by supervised cluster analysis for concordant mRNA and protein expression.
Methods
The current analysis includes women from the NBRST study, with histologically proven breast cancer, who received neo-adjuvant treatment, had 80-gene subtyping and provided written informed consent. Pathological assessment of HER2 was performed according to ASCO CAP guidelines at the time of diagnosis. 80-gene BluePrint (BP) classifies patients into Luminal, HER2 or Basal-type. pCR is defined as T0/isN0. All pCRs were verified with a de-identified copy of the surgical pathology report. Fisher's exact test was used to compare pCR rates within different subgroups.
Results
286 IHC/FISH HER2+ patients received c-t (175) or c-t-p (111). Of these 80-gene BP subtype classified 53% as HER2-type, 33% as Luminal-type and 14% as Basal-type. 64% were ER positive.
The pCR rates and p-values within different subgroups of clinical HER2+ patients are provided in the table below.
c-tc-t-p (n)pCR ratep-valueTotal (n=286)41%57%0.01BP HER2 (153)58%73%0.06 BP Luminal (93) 6% 39% 0.0002BP Basal (40)45%1.0IHC/FISH HER2+/ER+ (183)31%53%0.003IHC/FISH HER2+/ER- (103)59%64%0.68
Conclusions
One-third of ASCO/CAP Her2+ patients had 80-gene BP Luminal subtype and demonstrated resistance to c-t (pCR 6%). Addition of Pertuzumab overcame resistance in this group (pCR 39%). This finding in the neoadjuvant setting suggests a substantial potential benefit in the adjuvant setting and thus an urgent need to consider treatment in at-risk patients as well as confirmatory tissue analysis from independently reported trials.
Citation Format: Beitsch P, Whitworth P, Baron P, Beatty J, Pellicane JV, Murray MK, Dul C, Mislowsky AM, Nash CH, Richards PD, Lee LA, Stork-Sloots L, de Snoo F, Untch S, Gittleman M, Akbari S, Rotkis MC. One-third of HER2 positive patients have 80-gene luminal subtype that is resistant to chemo-trastuzumab but sensitive to chemo-trastuzumab-pertuzumab: Critical implications for the adjuvant setting from the NBRST phase 4 neoadjuvant study. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-14-29.
Collapse
Affiliation(s)
- P Beitsch
- Dallas Surgical Group, Dallas, TX; Nashville Breast Center; Breast & Melanoma Specialists of Charleston; The Breast Place, Charleston; Virginia Breast Center, Bon Secours Cancer Institute; Akron General Hospital; St. John Region; Coastal Carolina Breast Center; Northeast Georgia Medical Center; Blue Ridge Cancer Care; Comprehensive Cancer Center; Agendia Inc; Breast Care Specialists; Virginia Hospital Center; Northern Indiana Cancer Research Consortium
| | - P Whitworth
- Dallas Surgical Group, Dallas, TX; Nashville Breast Center; Breast & Melanoma Specialists of Charleston; The Breast Place, Charleston; Virginia Breast Center, Bon Secours Cancer Institute; Akron General Hospital; St. John Region; Coastal Carolina Breast Center; Northeast Georgia Medical Center; Blue Ridge Cancer Care; Comprehensive Cancer Center; Agendia Inc; Breast Care Specialists; Virginia Hospital Center; Northern Indiana Cancer Research Consortium
| | - P Baron
- Dallas Surgical Group, Dallas, TX; Nashville Breast Center; Breast & Melanoma Specialists of Charleston; The Breast Place, Charleston; Virginia Breast Center, Bon Secours Cancer Institute; Akron General Hospital; St. John Region; Coastal Carolina Breast Center; Northeast Georgia Medical Center; Blue Ridge Cancer Care; Comprehensive Cancer Center; Agendia Inc; Breast Care Specialists; Virginia Hospital Center; Northern Indiana Cancer Research Consortium
| | - J Beatty
- Dallas Surgical Group, Dallas, TX; Nashville Breast Center; Breast & Melanoma Specialists of Charleston; The Breast Place, Charleston; Virginia Breast Center, Bon Secours Cancer Institute; Akron General Hospital; St. John Region; Coastal Carolina Breast Center; Northeast Georgia Medical Center; Blue Ridge Cancer Care; Comprehensive Cancer Center; Agendia Inc; Breast Care Specialists; Virginia Hospital Center; Northern Indiana Cancer Research Consortium
| | - JV Pellicane
- Dallas Surgical Group, Dallas, TX; Nashville Breast Center; Breast & Melanoma Specialists of Charleston; The Breast Place, Charleston; Virginia Breast Center, Bon Secours Cancer Institute; Akron General Hospital; St. John Region; Coastal Carolina Breast Center; Northeast Georgia Medical Center; Blue Ridge Cancer Care; Comprehensive Cancer Center; Agendia Inc; Breast Care Specialists; Virginia Hospital Center; Northern Indiana Cancer Research Consortium
| | - MK Murray
- Dallas Surgical Group, Dallas, TX; Nashville Breast Center; Breast & Melanoma Specialists of Charleston; The Breast Place, Charleston; Virginia Breast Center, Bon Secours Cancer Institute; Akron General Hospital; St. John Region; Coastal Carolina Breast Center; Northeast Georgia Medical Center; Blue Ridge Cancer Care; Comprehensive Cancer Center; Agendia Inc; Breast Care Specialists; Virginia Hospital Center; Northern Indiana Cancer Research Consortium
| | - C Dul
- Dallas Surgical Group, Dallas, TX; Nashville Breast Center; Breast & Melanoma Specialists of Charleston; The Breast Place, Charleston; Virginia Breast Center, Bon Secours Cancer Institute; Akron General Hospital; St. John Region; Coastal Carolina Breast Center; Northeast Georgia Medical Center; Blue Ridge Cancer Care; Comprehensive Cancer Center; Agendia Inc; Breast Care Specialists; Virginia Hospital Center; Northern Indiana Cancer Research Consortium
| | - AM Mislowsky
- Dallas Surgical Group, Dallas, TX; Nashville Breast Center; Breast & Melanoma Specialists of Charleston; The Breast Place, Charleston; Virginia Breast Center, Bon Secours Cancer Institute; Akron General Hospital; St. John Region; Coastal Carolina Breast Center; Northeast Georgia Medical Center; Blue Ridge Cancer Care; Comprehensive Cancer Center; Agendia Inc; Breast Care Specialists; Virginia Hospital Center; Northern Indiana Cancer Research Consortium
| | - CH Nash
- Dallas Surgical Group, Dallas, TX; Nashville Breast Center; Breast & Melanoma Specialists of Charleston; The Breast Place, Charleston; Virginia Breast Center, Bon Secours Cancer Institute; Akron General Hospital; St. John Region; Coastal Carolina Breast Center; Northeast Georgia Medical Center; Blue Ridge Cancer Care; Comprehensive Cancer Center; Agendia Inc; Breast Care Specialists; Virginia Hospital Center; Northern Indiana Cancer Research Consortium
| | - PD Richards
- Dallas Surgical Group, Dallas, TX; Nashville Breast Center; Breast & Melanoma Specialists of Charleston; The Breast Place, Charleston; Virginia Breast Center, Bon Secours Cancer Institute; Akron General Hospital; St. John Region; Coastal Carolina Breast Center; Northeast Georgia Medical Center; Blue Ridge Cancer Care; Comprehensive Cancer Center; Agendia Inc; Breast Care Specialists; Virginia Hospital Center; Northern Indiana Cancer Research Consortium
| | - LA Lee
- Dallas Surgical Group, Dallas, TX; Nashville Breast Center; Breast & Melanoma Specialists of Charleston; The Breast Place, Charleston; Virginia Breast Center, Bon Secours Cancer Institute; Akron General Hospital; St. John Region; Coastal Carolina Breast Center; Northeast Georgia Medical Center; Blue Ridge Cancer Care; Comprehensive Cancer Center; Agendia Inc; Breast Care Specialists; Virginia Hospital Center; Northern Indiana Cancer Research Consortium
| | - L Stork-Sloots
- Dallas Surgical Group, Dallas, TX; Nashville Breast Center; Breast & Melanoma Specialists of Charleston; The Breast Place, Charleston; Virginia Breast Center, Bon Secours Cancer Institute; Akron General Hospital; St. John Region; Coastal Carolina Breast Center; Northeast Georgia Medical Center; Blue Ridge Cancer Care; Comprehensive Cancer Center; Agendia Inc; Breast Care Specialists; Virginia Hospital Center; Northern Indiana Cancer Research Consortium
| | - F de Snoo
- Dallas Surgical Group, Dallas, TX; Nashville Breast Center; Breast & Melanoma Specialists of Charleston; The Breast Place, Charleston; Virginia Breast Center, Bon Secours Cancer Institute; Akron General Hospital; St. John Region; Coastal Carolina Breast Center; Northeast Georgia Medical Center; Blue Ridge Cancer Care; Comprehensive Cancer Center; Agendia Inc; Breast Care Specialists; Virginia Hospital Center; Northern Indiana Cancer Research Consortium
| | - S Untch
- Dallas Surgical Group, Dallas, TX; Nashville Breast Center; Breast & Melanoma Specialists of Charleston; The Breast Place, Charleston; Virginia Breast Center, Bon Secours Cancer Institute; Akron General Hospital; St. John Region; Coastal Carolina Breast Center; Northeast Georgia Medical Center; Blue Ridge Cancer Care; Comprehensive Cancer Center; Agendia Inc; Breast Care Specialists; Virginia Hospital Center; Northern Indiana Cancer Research Consortium
| | - M Gittleman
- Dallas Surgical Group, Dallas, TX; Nashville Breast Center; Breast & Melanoma Specialists of Charleston; The Breast Place, Charleston; Virginia Breast Center, Bon Secours Cancer Institute; Akron General Hospital; St. John Region; Coastal Carolina Breast Center; Northeast Georgia Medical Center; Blue Ridge Cancer Care; Comprehensive Cancer Center; Agendia Inc; Breast Care Specialists; Virginia Hospital Center; Northern Indiana Cancer Research Consortium
| | - S Akbari
- Dallas Surgical Group, Dallas, TX; Nashville Breast Center; Breast & Melanoma Specialists of Charleston; The Breast Place, Charleston; Virginia Breast Center, Bon Secours Cancer Institute; Akron General Hospital; St. John Region; Coastal Carolina Breast Center; Northeast Georgia Medical Center; Blue Ridge Cancer Care; Comprehensive Cancer Center; Agendia Inc; Breast Care Specialists; Virginia Hospital Center; Northern Indiana Cancer Research Consortium
| | - MC Rotkis
- Dallas Surgical Group, Dallas, TX; Nashville Breast Center; Breast & Melanoma Specialists of Charleston; The Breast Place, Charleston; Virginia Breast Center, Bon Secours Cancer Institute; Akron General Hospital; St. John Region; Coastal Carolina Breast Center; Northeast Georgia Medical Center; Blue Ridge Cancer Care; Comprehensive Cancer Center; Agendia Inc; Breast Care Specialists; Virginia Hospital Center; Northern Indiana Cancer Research Consortium
| |
Collapse
|
8
|
Li HY, Lee LA, Yu JF, Lo YL, Chen NH, Fang TJ, Hsin LJ, Lin WN, Huang CG, Cheng WN. Changes of snoring sound after relocation pharyngoplasty for obstructive sleep apnoea: the surgery reduces mean intensity in snoring which correlates well with apnoea-hypopnoea index. Clin Otolaryngol 2016; 40:98-105. [PMID: 25311724 DOI: 10.1111/coa.12325] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/05/2014] [Indexed: 11/29/2022]
Abstract
OBJECTIVE To investigate objective changes of snoring after surgery in patients with obstructive sleep apnoea (OSA) and correlate these with changes in the apnoea-hypopnoea index (AHI). DESIGN Prospective case series. SETTING A novel measurement, Snore Map, was used to analyse full-night snore sounds in terms of the maximal/mean intensity, peak/mean frequency, snoring index and energy type (Snore Map type, 0-4). Snore sound was classified into three bands according to frequency energy spectrum: B1 (40-300 Hz), B2 (301-850 Hz) and B3 (851-2000 Hz). PARTICIPANTS Thirty-four male and two female OSA patients (mean age, 39 years; mean AHI, 53.1/h; mean body mass index, 26.8 kg/m(2) ) with favourable anatomic structure were consecutively enrolled. MAIN OUTCOME MEASURES Parameters of polysomnographies and Snore Maps at baseline and six months after operation were compared. Statistical significance was set at P < 0.05. RESULTS Thirty-two patients completed this study. The mean reduction in the total-snoring index was insignificant but there were significant decreases in total mean intensity, total peak frequency, total mean frequency and Snore Map type after surgery. There were also significant decreases in the mean intensity in all three bands, the snoring index in B2/B3 and the mean frequency in B1 postoperatively. Changes in the total mean intensity, total mean frequency, B2 mean intensity and B3 snoring index positively correlated with change in the AHI. CONCLUSIONS Relocation pharyngoplasty significantly decreases both the snoring sound intensity and snoring frequency. These reductions are directly proportional to the improvement of OSA.
Collapse
Affiliation(s)
- H Y Li
- Department of Otolaryngology, Sleep Center, Linkou Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan; Department of Sleep Medicine, Royal Infirmary Edinburgh, Edinburgh, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Clarke JO, Sharaiha RZ, Kord Valeshabad A, Lee LA, Kalloo AN, Khashab MA. Through-the-scope transpyloric stent placement improves symptoms and gastric emptying in patients with gastroparesis. Endoscopy 2014; 45 Suppl 2 UCTN:E189-90. [PMID: 23824975 DOI: 10.1055/s-0032-1326400] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Affiliation(s)
- J O Clarke
- Department of Medicine and Division of Gastroenterology and Hepatology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
| | | | | | | | | | | |
Collapse
|
10
|
Abstract
Cutaneous lupus may occur in infancy as transient lesions associated with and probably caused by maternal autoantibodies, or later in childhood, associated with the endogenous development of autoimmunity. In this review, clinical findings, diagnosis, management, and pathogenesis of neonatal lupus are discussed, and the management of cutaneous lupus in children is detailed.
Collapse
Affiliation(s)
- L A Lee
- Dermatology Service, Denver Health Medical Center, Denver, CO 80204, USA.
| |
Collapse
|
11
|
Klein RQ, Bangert CA, Costner M, Connolly MK, Tanikawa A, Okawa J, Rose M, Fakharzadeh SS, Fiorentino D, Lee LA, Sontheimer RD, Taylor L, Troxel AB, Werth VP. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 2008; 159:887-94. [PMID: 18616782 DOI: 10.1111/j.1365-2133.2008.08711.x] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Reliable and validated measures of skin disease severity are needed for cutaneous dermatomyositis (DM). Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Dermatomyositis Skin Severity Index (DSSI) and Cutaneous Assessment Tool (CAT) skin indices have been developed as outcome instruments. OBJECTIVES We sought to demonstrate reliability and validity of the CDASI, and to compare the CDASI with other potential tools for use in measuring disease severity in cutaneous dermatomyositis. PATIENTS AND METHODS CDASI has four activity and two damage measures, with scores from 0 to 148. DSSI assesses activity based on body surface area and severity on a scale of 0-72. CAT uses 21 activity and damage items, for a range of 0-175 for activity and 0-33 for damage. Ten dermatologists used the instruments to score the same 12-16 patients in one session. Global validation measures were administered to physicians and patients. RESULTS Global validation measures correlated with the three outcome instruments (P < 0.0001). CAT displayed lower inter- and intrarater reliability relative to the CDASI. All scales correlate better with physician than patient global skin measures. CONCLUSIONS It appears that the CDASI may be a useful outcome measure for studies of cutaneous DM. Further testing to compare responsiveness of all three measures is necessary.
Collapse
Affiliation(s)
- R Q Klein
- Department of Dermatology, School of Medicine, University of Pennsylvania, 3600 Spruce Street, 2 Maloney Building, Philadelphia, PA 19104, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Hendrix CW, Fuchs EJ, Macura KJ, Lee LA, Parsons TL, Bakshi RP, Khan WA, Guidos A, Leal JP, Wahl R. Quantitative imaging and sigmoidoscopy to assess distribution of rectal microbicide surrogates. Clin Pharmacol Ther 2007; 83:97-105. [PMID: 17507921 DOI: 10.1038/sj.clpt.6100236] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Understanding the distribution of microbicide and human immunodeficiency virus (HIV) within the gastrointestinal tract is critical to development of rectal HIV microbicides. A hydroxyethylcellulose-based microbicide surrogate or viscosity-matched semen surrogate, labeled with gadolinium-DTPA (diethylene triamine pentaacetic acid) and 99mTechnetium-sulfur colloid, was administered to three subjects under varying experimental conditions to evaluate effects of enema, coital simulation, and microbicide or semen simulant over 5 h duration. Quantitative assessment used single photon emission computed tomography (SPECT)/computed tomography (CT) and magnetic resonance imaging (MRI) imaging, and sigmoidoscopic sampling. Over 4 h, radiolabel migrated cephalad in all studies by a median (interquartile range) of 50% (29-102%; P<0.001), as far as the splenic flexure (approximately 60 cm) in 12% of studies. There was a correlation in concentration profile between endoscopic sampling and SPECT assessments. HIV-sized particles migrate retrograde, 60 cm in some studies, 4 h after simulated ejaculation in our model. SPECT/CT, MRI, and endoscopy can be used quantitatively to facilitate rational development of microbicides for rectal use.
Collapse
Affiliation(s)
- C W Hendrix
- Department of Medicine, Division of Clinical Pharmacology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Juhn YJ, Kita H, Lee LA, Smith RW, Bagniewski SM, Weaver AL, Pankratz VS, Jacobson RM, Poland GA. Childhood asthma and human leukocyte antigen type. ACTA ACUST UNITED AC 2007; 69:38-46. [PMID: 17212706 DOI: 10.1111/j.1399-0039.2006.00719.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Little is known about the relationship between human leukocyte antigen (HLA) class II genes and family history of asthma or atopy in relation to the incidence of childhood asthma. The objective of the study was to determine whether specific HLA class II genes (e.g., DRB1*03) are associated with asthma and whether such association explains the influences of family history of asthma or atopy on asthma incidence. A stratified random sample of 340 children who had HLA data available from the Rochester Family Measles Study cohort (n= 876) and a convenience sample of healthy children aged 5-12 years were the participants. We conducted comprehensive medical record reviews to determine asthma status of these children. The associations between the presence of specific HLA alleles and development of asthma and the role of family history of asthma or atopy in the association were evaluated by fitting Cox models. The cumulative incidence of asthma by 12 years of age among children who carry HLA DRB1*03 was 33%, compared to 24.2% among those who did not carry this allele. Adjusting for family history of asthma or atopy, gender, low birth weight, season of birth, HLA DRB1*04, and HLA DQB1*0302, the hazards ratio for HLA DRB1*03 carriers was 1.8 (95% confidence interval: 1.1-2.9, P= 0.020). We concluded that the HLA DRB1*03 allele is associated with asthma. However, the HLA class II gene does not explain the influences of family history of asthma or atopy on development of asthma. The mechanism underlying the association between asthma and HLA genes needs to be elucidated.
Collapse
Affiliation(s)
- Y J Juhn
- Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN 55905, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Banani N, Lee LA, Holl MR, Marquardt B, Troll M, Wilson DM. SLAP: design software for optimization of fluorescence analysis systems. Conf Proc IEEE Eng Med Biol Soc 2007; 2004:2086-9. [PMID: 17272133 DOI: 10.1109/iembs.2004.1403613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
Initial results of a comprehensive design software that optimizes parameters for fluorescence analysis of a user-defined fluorophore are presented. SLAP (spectral LED aggregation program) automatically selects configurations of LEDs that, in a fluorescence analysis system, maximize the emission signal (useful output) as a function of the excitation signal (interference), optics, photodetection modality, and sample characteristics. Initial results draw on an extensive database of blue, blue-green, green and purple LEDs characterized across a range of nominal and overdrive operating conditions. Overdrive conditions enable spectral shifts of the LED excitation bands to enhance the overall flexibility of SLAP optimization. Representative results show a 70.1% improvement in collected signal for GFPuv fluorophores when compared to conventional LED-based fluorescence operated under nominal operating conditions.
Collapse
Affiliation(s)
- N Banani
- Department of Electrical Engineering, University of Washington, Seattle, WA 98195, USA
| | | | | | | | | | | |
Collapse
|
15
|
Abstract
The c-Myc oncogenic transcription factor plays a central role in many human cancers through the regulation of gene expression. Although the molecular mechanisms by which c-Myc and its obligate partner, Max, regulate gene expression are becoming better defined, genes or transcriptomes that c-Myc regulate are just emerging from a variety of different experimental approaches. Studies of individual c-Myc target genes and their functional implications are now complemented by large surveys of c-Myc target genes through the use of subtraction cloning, DNA microarray analysis, serial analysis of gene expression (SAGE), chromatin immunoprecipitation, and genome marking methods. To fully appreciate the differences between physiological c-Myc function in normal cells and deregulated c-Myc function in tumors, the challenge now is to determine how the authenticated transcriptomes effect the various phenotypes induced by c-Myc and to define how c-Myc transcriptomes are altered by the Mad family of proteins.
Collapse
Affiliation(s)
- L A Lee
- Department of Medicine, The Johns Hopkins University School of Medicine, Ross 1032, 720 Rutland Avenue, Baltimore, MD 21205, USA.
| | | |
Collapse
|
16
|
Lee LA, Soderholm SC, Flemmer MM, Hornsby-Myers JL. Field test results of an automated exposure assessment tool, the local positioning system (LPS). ACTA ACUST UNITED AC 2005; 7:736-42. [PMID: 15986055 DOI: 10.1039/b503581c] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A user-friendly environmental monitoring system that collects real time data has been developed. Flash card memory logs exposure data from multiple sensors along with corresponding times and positions. Optional use of telemetry repeaters and a reference station allows central monitoring of data to assess exposure and to initiate intervention when safe levels are exceeded. A software analysis package allows researchers to identify exposure hot spots and direct control efforts, with the ultimate goal being to reduce injury and disease. Preliminary field test results document position accuracy and system performance in harsh environments.
Collapse
Affiliation(s)
- L A Lee
- National Institute for Occupational Safety and Health, Health Effects Laboratory Division, Morgantown, WV, USA
| | | | | | | |
Collapse
|
17
|
Albrecht J, Berlin JA, Braverman IM, Callen JP, Connolly MK, Costner MI, Dutz J, Fivenson D, Franks AG, Jorizzo JL, Lee LA, McCauliffe DP, Sontheimer RD, Werth VP. Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus. Lupus 2005; 13:839-49. [PMID: 15580979 DOI: 10.1191/0961203304lu2020oa] [Citation(s) in RCA: 90] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The 1982 ACR classification criteria have become de facto diagnostic criteria for systemic lupus erythematosus (SLE), but a review of the criteria is necessary to include recent diagnostic tests. The criteria were not developed with the help of dermatologists, and assign too much weight to the skin as one expression of a multiorgan disease. Consequently, patients with skin diseases are classified as SLE based mostly on skin symptoms. We discuss specific problems with each dermatologic criterion, but changes must await a new study. We suggest the following guidelines for such a study, aimed at revision of the criteria. 1) The SLE patient group should be recruited in part by dermatologists. 2) The study should evaluate an appropriate international ethnic/racial mix, including late onset SLE as well as pediatric patients. 3) All patients should have current laboratory and clinical evaluations, as suggested in the paper, to assure the criteria can be up-to-date. This includes anti-SS-A and anti-SS-B antibodies and skin biopsies for suspected cutaneous lupus erythematosus except for nonscarring alopecia and oral ulcers. 4) The study should be based on a series of transparent power calculations. 5) The control groups should represent relevant differential diagnoses in numbers large enough to assess diagnostic problems that might be specific to these differential diagnoses. In order to demonstrate specificity of the criteria with a 95% confidence interval between 90 and 100%, each control group of the above should have at least 73 patients.
Collapse
Affiliation(s)
- J Albrecht
- Department of Dermatology, University of Pennsylvania, PA, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Fang TJ, Li HY, Shue CW, Lee LA, Wang PC. Efficacy of radiofrequency volumetric tissue reduction of the soft palate in the treatment of snoring. Int J Clin Pract 2003; 57:769-72. [PMID: 14686565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
Abstract
Traditional surgery for snoring often leads to intolerable postoperative pain. A new surgical treatment, radiofrequency volumetric tissue reduction (RVTR) of the soft palate, was carried out and its effect and safety in the management of snoring were evaluated. Thirty-two patients received a single treatment of RVTR with a mean follow-up period of 4.5 months. All patients were assessed by a questionnaire using the Snore Outcomes Survey (SOS) and the Epworth Sleepiness Scale (ESS). Postoperative pain, speech and swallowing disturbances were also evaluated. The postoperative scores of SOS and ESS all significantly improved (p<0.05). Postoperative pain, speech and swallowing disturbances were all mild 1-3 days after treatment. With the success of treatment defined as a postoperative snoring index (SI) of <3 or a reduction of the SI by >5 points by the visual analogue scale, the success rate was 81.3% in patients with a respiratory disturbance index (RDI) of <20, and 50% in those with an RDI of >20. We conclude that RVTR of the soft palate is an effective treatment for snoring, resulting in only mild postoperative discomfort. A patient whose RDI was <20 had a higher success rate with a single RVTR treatment.
Collapse
Affiliation(s)
- T J Fang
- Department of Otolaryngology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
| | | | | | | | | |
Collapse
|
19
|
Abstract
INTRODUCTION Little is known about cerebral autoregulation in children. The aim of this study was to examine cerebral autoregulation in children. METHODS Cerebral autoregulation testing was performed during less than 1 MAC sevoflurane anaesthesia in children (from 6 months to 14 yr) and in adults (18-41 yr). Mean middle cerebral artery flow velocities (V(MCA)) were measured using transcranial Doppler ultrasonography. Mean arterial pressure (MAP) was increased to whichever was greater: 20% above baseline or (i) 80 mm Hg for less than 9 yr, (ii) 90 mm Hg for 9-14 yr, and (iii) 100 mm Hg for adults. Cerebral autoregulation was considered intact if the autoregulatory index was > or =0.4. RESULTS There were 13 subjects less than 2 yr old (Group 1), 13 subjects 2-5 yr (Group II), 14 subjects 6-9 yr (Group III), 12 subjects 10-14 yr (Group IV), and 12 adults (Group V; control group). All subjects had an autoregulatory index > or =0.4. There was no difference in autoregulatory index between children in Groups I-IV or between children and adults. DISCUSSION We found no age-related differences in autoregulatory capacity during low-dose sevoflurane anaesthesia. We report no differences in autoregulatory capacity between children and adults.
Collapse
Affiliation(s)
- M S Vavilala
- Department of Anesthesiology, University of Washington, Seattle 98104, USA.
| | | | | | | | | | | |
Collapse
|
20
|
Cruz-Correa M, Poonawala A, Abraham SC, Wu TT, Zahurak M, Vogelsang G, Kalloo AN, Lee LA. Endoscopic findings predict the histologic diagnosis in gastrointestinal graft-versus-host disease. Endoscopy 2002; 34:808-13. [PMID: 12244503 DOI: 10.1055/s-2002-34257] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND AND STUDY AIMS Graft-versus-host disease (GvHD) of the gastrointestinal tract is a major cause of morbidity and mortality after allogeneic bone marrow transplantation (BMT). Whether endoscopic findings predict the histologic diagnosis of GvHD in the gastrointestinal tract remains controversial. We performed a study to determine the diagnostic accuracy of macroscopic endoscopy findings in the diagnosis of acute and chronic histologically proven gastrointestinal GvHD (GI-GvHD). PATIENTS AND METHODS Endoscopic images from the intestinal mucosa of post-BMT patients were blindly graded as positive or negative for GI-GvHD and compared with corresponding histological findings, which were used as the gold standard. RESULTS 44 BMT patients were referred for 96 endoscopic evaluations. Using 162 endoscopy-biopsy pairs, a positive association between endoscopic grading and histologic grading of GI-GvHD (odds ratio [OR] = 11.97, 95% CI 3.86, 37.16) was observed. Endoscopic diagnosis correctly predicted histologic diagnosis in both acute and chronic GI-GvHD (OR = 9.3 vs. 23.1, P = 0.31). CONCLUSIONS The diagnostic accuracy of endoscopy was high in both acute and chronic histologically proven GI-GvHD. Accurate diagnosis of GI-GvHD might be obtained with mucosal biopsies from either the upper or lower gastrointestinal tract. Endoscopy may play a significant role in establishing early diagnosis and treatment for GI-GvHD in patients following BMT, but histologic evaluation of the gastrointestinal mucosa is needed to confirm the final diagnosis.
Collapse
Affiliation(s)
- M Cruz-Correa
- Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Abstract
Few cases of inflammatory blaschkolinear dermatoses have been described. We report a case of blaschkolinear cutaneous tumid lupus erythematous and discuss the potential association between cutaneous genetic mosaicism, Blaschko lines and lupus susceptibility.
Collapse
|
22
|
Sharar SR, Carrougher GJ, Selzer K, O'Donnell F, Vavilala MS, Lee LA. A comparison of oral transmucosal fentanyl citrate and oral oxycodone for pediatric outpatient wound care. J Burn Care Rehabil 2002; 23:27-31. [PMID: 11803309 DOI: 10.1097/00004630-200201000-00006] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Analgesia for pediatric burn wound care in the outpatient clinic is constrained by time, personnel, and/or monitoring capabilities, yet may improve patient satisfaction and comfort, clinic efficiency, and patient throughput. The ideal analgesic in this increasingly common setting should be palatable, provide potent, rapid, and brief analgesia, and require minimal appropriate monitoring. Using a placebo-controlled, double-blind design we compared oral transmucosal fentanyl citrate (OTFC, approximately 10 microg/kg) and oral oxycodone (0.2 mg/kg) in 22 pediatric outpatient wound care procedures (ages 5-14 years). Pulse oximetry, vital signs, side effects, patient pain scores, and observer scores for cooperation, anxiety, and sedation were recorded. OTFC and oral oxycodone resulted in similar outcome measures and vital signs, and no significant side effects. The taste of OTFC was preferred. We conclude that OTFC and oral oxycodone are safe and effective analgesics in the setting of monitored outpatient wound care in children, and that OTFC offers the advantage of improved palatability.
Collapse
Affiliation(s)
- S R Sharar
- Department of Anesthesiology, University of Washington School of Medicine and Harborview Medical Center, Seattle, Washington 98104, USA
| | | | | | | | | | | |
Collapse
|
23
|
Prescott JE, Osthus RC, Lee LA, Lewis BC, Shim H, Barrett JF, Guo Q, Hawkins AL, Griffin CA, Dang CV. A novel c-Myc-responsive gene, JPO1, participates in neoplastic transformation. J Biol Chem 2001; 276:48276-84. [PMID: 11598121 DOI: 10.1074/jbc.m107357200] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We have identified a novel c-Myc-responsive gene, named JPO1, by representational difference analysis. JPO1 responds to two inducible c-Myc systems and behaves as a direct c-Myc target gene. JPO1 mRNA expression is readily detectable in the thymus, small intestine, and colon, whereas expression is relatively low in spleen, bone marrow, and peripheral leukocytes. We cloned a full-length JPO1 cDNA that encodes a 47-kDa nuclear protein. To determine the role of JPO1 in Myc-mediated cellular phenotypes, stable Rat1a fibroblasts overexpressing JPO1 were tested and compared with transformed Rat1a-Myc cells. Although JPO1 has a diminished transforming activity as compared with c-Myc, JPO1 complements a transformation-defective Myc Box II mutant in the Rat1a transformation assay. This complementation provides evidence for a genetic link between c-Myc and JPO1. Similar to c-Myc, JPO1 overexpression enhances the clonogenicity of CB33 human lymphoblastoid cells in methylcellulose assays. These observations suggest that JPO1 participates in c-Myc-mediated transformation, supporting an emerging concept that c-Myc target genes constitute nodal points in a network of pathways that lead from c-Myc to various Myc-related phenotypes and ultimately to tumorigenesis.
Collapse
Affiliation(s)
- J E Prescott
- Program in Human Genetics and Molecular Biology, Department of Medicine, Johns Hopkins Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205,USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Lin LL, Shih YF, Hsiao CK, Chen CJ, Lee LA, Hung PT. Epidemiologic study of the prevalence and severity of myopia among schoolchildren in Taiwan in 2000. J Formos Med Assoc 2001; 100:684-91. [PMID: 11760374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023] Open
Abstract
BACKGROUND AND PURPOSE A nationwide survey was performed in 2000 to determine the prevalence and severity of myopia among schoolchildren in Taiwan and to compare these findings with the results of the last survey performed in 1995. METHODS We first divided the whole island into regions according to developmental grade scores and then sampled with the probability proportional to the size of the population within each stratum. A total of 10,889 students were enrolled, including 5,664 boys and 5,225 girls, with ages ranging from 7 to 18 years. The refractive status and corneal radius of each student were measured with an autorefractometer under cycloplegia and checked with retinoscopy. Axial length was measured using biometric ultrasound. RESULTS The myopia rate increased from 20% at 7 years, to 61% at 12 years, and 81% at 15 years. A myopic rate of 84% was found for schoolchildren aged 16 years through 18 years. The mean refractive index reached myopic status at the age of 8, and increased to -4.12 D in girls and -3.15 D in boys at the age of 18 years. The prevalence of high myopia (> -6.0 D) at the age of 18 years was 24% in girls and 18% in boys. The increase in axial length corresponded with the progression of myopia. The anterior chamber depth was slightly deeper from 7 years to 13 years and then remained stable. The lens thickness decreased from 7 years to 11 years. After age 15, further thickening of the lens was correlated with both age and severity of myopia. However, the corneal curvature was not related to age or severity of myopia. Girls had a higher prevalence and more severe degree of myopia than boys. Children in urban areas had a higher prevalence and more severe degree of myopia than children in rural areas. CONCLUSION The prevalence and severity of myopia in schoolchildren in Taiwan in 2000 increased compared to 1995, with the most severe increases occurring in younger age groups. Thus, preventing schoolchildren developing myopia at a young age may slow down the increase in severity of myopia in Taiwan.
Collapse
Affiliation(s)
- L L Lin
- Department of Ophthalmology, College of Medicine and Hospital, Taipei, Taiwan
| | | | | | | | | | | |
Collapse
|
25
|
Affiliation(s)
- R Garg
- Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 4770 Buford Highway, Atlanta, GA 30341, USA
| | | | | | | | | |
Collapse
|
26
|
Abstract
Neonatal lupus is a disease characterized by one or more of the following findings: congenital heart block, cardiomyopathy, cutaneous lupus lesions, hepatobiliary disease, and thrombocytopenia. Accumulating evidence indicates that the disease is probably caused by maternal autoantibodies, particularly autoantibodies of the Ro family. While often initially asymptomatic, mothers tend to develop symptoms of connective tissue disease. This review discusses the recent advances in the understanding of neonatal lupus, its clinical features, therapy, and pathogenesis.
Collapse
Affiliation(s)
- L A Lee
- Department of Dermatology, University of Colorado School of Medicine, 4200 East Ninth Avenue, Denver, CO 80262, USA.
| |
Collapse
|
27
|
Abstract
The human homolog of KET, p63, bears strong homology to the tumor suppressor p53 and plays an essential role in epithelial development. CUSP, the most abundant cutaneous product of p63, has been identified as an autoantigen in chronic ulcerative stomatitis (CUS). The original report of KET expression at least partially contradicts p63 expression subsequently reported by many different groups. We have examined p63 expression by Northern analysis of RNA from multiple human tissues and by indirect immunofluorescence of rat tissue with CUS patient sera. Northern analysis reveals p63 RNA in skin, thymus, placenta, skeletal muscle, kidney, and lung, with non-transactivating p63 RNA in skin, thymus, and placenta. Reverse transcriptase polymerase chain reaction (rtPCR) assays show abundant non-transactivating p63 RNA, and little to no transactivating p63 RNA, in human basal cell carcinoma as well as in normal skin adjacent to the tumors. p63 RNA expression was not detected in brain, heart, colon, spleen, liver, or small intestine. Immunofluorescence reveals p63 expression in skin, oral epithelium, tongue, kidney, and trachea, but not in liver, large intestine, testis, skeletal muscle, or heart. Focal p63 expression within tissues, the complex array of isoforms encoded by the gene, and the specificity of the probes and antibodies utilized, may all contribute to contradictory accounts of CUSP/p63 expression.
Collapse
Affiliation(s)
- R P Dellavalle
- Department of Dermatology, University of Colorado School of Medicine, B-153, 4200 E. Ninth Avenue, Denver, CO 90262, USA
| | | | | | | | | | | |
Collapse
|
28
|
Affiliation(s)
- L A Lee
- Department of Anesthesiology, Harborview Medical Center, University of Washington School of Medicine, Seattle 98104, USA
| | | |
Collapse
|
29
|
Affiliation(s)
- L A Lee
- Division of Gastroenterology, The Johns Hopkins University School of Medicine, 720 Rutland Avenue, Ross 1012, Baltimore, Maryland 21205, USA.
| |
Collapse
|
30
|
Affiliation(s)
- L A Lee
- Division of Gastroenterology, The Johns Hopkins University School of Medicine, 720 Rutland Avenue, Ross 1012, Baltimore, Maryland 21205, USA.
| |
Collapse
|
31
|
Lee LA, Elfring LK, Bosco G, Orr-Weaver TL. A genetic screen for suppressors and enhancers of the Drosophila PAN GU cell cycle kinase identifies cyclin B as a target. Genetics 2001; 158:1545-56. [PMID: 11514446 PMCID: PMC1461742 DOI: 10.1093/genetics/158.4.1545] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
The early cell cycles of Drosophila embryogenesis involve rapid oscillations between S phase and mitosis. These unique S-M cycles are driven by maternal stockpiles of components necessary for DNA replication and mitosis. Three genes, pan gu (png), plutonium (plu), and giant nuclei (gnu) are required to control the cell cycle specifically at the onset of Drosophila development by inhibiting DNA replication and promoting mitosis. PNG is a protein kinase that is in a complex with PLU. We employed a sensitized png mutant phenotype to screen for genes that when reduced in dosage would dominantly suppress or enhance png. We screened deficiencies covering over 50% of the autosomes and identified both enhancers and suppressors. Mutations in eIF-5A and PP1 87B dominantly suppress png. Cyclin B was shown to be a key PNG target. Mutations in cyclin B dominantly enhance png, whereas png is suppressed by cyclin B overexpression. Suppression occurs via restoration of Cyclin B protein levels that are decreased in png mutants. The plu and gnu phenotypes are also suppressed by cyclin B overexpression. These studies demonstrate that a crucial function of PNG in controlling the cell cycle is to permit the accumulation of adequate levels of Cyclin B protein.
Collapse
Affiliation(s)
- L A Lee
- Whitehead Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
| | | | | | | |
Collapse
|
32
|
Abstract
The authors present the case of an anemic 22-month-old child undergoing lower extremity surgery in whom the lower limit of cerebral autoregulation was shifted to the right.
Collapse
Affiliation(s)
- M S Vavilala
- Department of Anesthesiology, Harborview Medical Center, University of Washington School of Medicine, Seattle, Washington 98104, USA
| | | | | | | |
Collapse
|
33
|
Affiliation(s)
- P Gibbs
- Department of Dermatology, University of Colorado School of Medicine, Denver, Colorado 80262, USA
| | | | | | | |
Collapse
|
34
|
Abraham SC, Bhagavan BS, Lee LA, Rashid A, Wu TT. Upper gastrointestinal tract injury in patients receiving kayexalate (sodium polystyrene sulfonate) in sorbitol: clinical, endoscopic, and histopathologic findings. Am J Surg Pathol 2001; 25:637-44. [PMID: 11342776 DOI: 10.1097/00000478-200105000-00011] [Citation(s) in RCA: 182] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Kayexalate (sodium polystyrene sulfonate) in sorbitol has been demonstrated to cause colonic necrosis in a subset of uremic patients who are administered the cation exchange resin for treatment of hyperkalemia. Upper gastrointestinal damage associated with Kayexalate in sorbitol is reported far less frequently, and the clinicopathologic spectrum of disease in cases with upper gastrointestinal damage has not been investigated previously. The authors studied the clinical, endoscopic, and histologic features of 11 patients with Kayexalate crystals in biopsies from the esophagus (n = 7), stomach (n = 6), and duodenum (n = 2). The endoscopic appearance was markedly abnormal in all 11 patients. The effects of the medication closely mimicked other endoscopic and radiologic diagnoses in three cases, including esophageal carcinoma, Candidal esophagitis, and gastric bezoar. Histologic and/or endoscopic evidence of mucosal injury in the form of an ulcer or erosion was present in nine patients (82%). In four patients with mucosal injury, no other etiology apart from Kayexalate in sorbitol could be identified. In comparison with a cohort of patients with Kayexalate crystals in lower gastrointestinal specimens identified during the same period (11 patients) the frequency of associated mucosal damage was not significantly different (55%, p = 0.19), but no patient with upper gastrointestinal Kayexalate required surgical resection or died as a result of Kayexalate-induced mucosal injury. The results of this study provide evidence that Kayexalate in sorbitol can induce damage to the upper gastrointestinal tract. Recognition of Kayexalate crystals in histologic sections as a marker for sorbitol-induced mucosal damage may aid in establishing the correct diagnosis for clinically or endoscopically misleading lesions.
Collapse
Affiliation(s)
- S C Abraham
- Division of Gastrointestinal/Liver Pathology, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205-2196, USA.
| | | | | | | | | |
Collapse
|
35
|
Abstract
Behçet's disease is a multisystem inflammatory disorder of unknown origin, characterized by recurrent oral and genital ulcerations, ocular and cutaneous lesions, arthritis, central nervous system, and vascular disease. There is no pathognomonic laboratory test, but there are clinical criteria to assist in establishing the diagnosis. Behçet's is most common along the Silk Road. It is particularly common among persons who have the HLA-B51 major histocompatibility type. Cutaneous lesions include pustules, erythema nodosum-like lesions, Sweet's-like lesions, pyoderma gangrenosum-ike lesions, and pathergy. The major cutaneous findings may be classified as neutrophilic vascular reactions. There is considerable morbidity resulting from Behçet's disease, most notably a high risk of blindness from ocular involvement. Mortality may occur as a result of neurologic or vascular disease or gastrointestinal perforation.
Collapse
Affiliation(s)
- L A Lee
- Department of Dermatology, University of Colorado School of Medicine, Denver, USA.
| |
Collapse
|
36
|
Kim S, Zeller K, Dang CV, Sandgren EP, Lee LA. A strategy to identify differentially expressed genes using representational difference analysis and cDNA arrays. Anal Biochem 2001; 288:141-148. [PMID: 11152584 DOI: 10.1006/abio.2000.4900] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Representational difference analysis (RDA) combined with cDNA arrays is an effective approach to identify differentially expressed genes. To identify differentially expressed genes in c-Myc transgenic mouse liver, we compared the virtues of probing commercially available cDNA arrays with either radiolabeled cDNA pools or radiolabeled difference products (DP2) derived from RDA using c-Myc transgenic and normal mouse liver. Probing commercial and custom arrays with DP2 products led to the identification of transcripts of low abundance that were missed when the arrays were initially probed with PCR-amplified cDNA pools. Although DP2 probes also detected abundant transcripts that are highly differentially expressed, they failed to identify abundant transcripts with low differential expression that were detected with cDNA pools. The combined use of radiolabeled cDNA and DP2 products to probe arrays allows a more comprehensive identification of differentially expressed transcripts that are abundant or rare. Our method has the additional benefit of eliminating false-positive transcripts that lack true differential expression and frequently contaminate DP2 pools. Using this method we identified 16 differentially expressed genes in c-Myc transgenic liver, one of which is novel.
Collapse
Affiliation(s)
- S Kim
- Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, 21205, USA
| | | | | | | | | |
Collapse
|
37
|
Abstract
We highlight the involvement of community health, public health and mental health staff in the recovery period after a natural disaster (hailstorm and ensuing wind and rain over three weeks) which, despite causing relatively few deaths or severe injuries, affected 20,000 families and caused damage estimated at $1.5 billion. Many families were given information and advice, and 383 individuals were referred for health assessment and management by doctors and other healthcare workers over an eight-month recovery period.
Collapse
Affiliation(s)
- L A Lee
- South Eastern Sydney Area Health Service, NSW.
| | | |
Collapse
|
38
|
Neiman AR, Lee LA, Weston WL, Buyon JP. Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry. J Pediatr 2000; 137:674-80. [PMID: 11060534 DOI: 10.1067/mpd.2000.109108] [Citation(s) in RCA: 185] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
OBJECTIVE To extend the information base on cutaneous manifestations of neonatal lupus erythematosus (NLE) with regard to maternal disease, sex of child, onset, localization, influence of UV light, prognosis, and recurrence rates in subsequent pregnancies. METHODS Review of records from the Research Registry for Neonatal Lupus. RESULTS The cohort includes 47 mothers (83% white) whose sera contain anti-SSA/Ro, anti-SSB/La, and/or anti-U1-ribonucleoprotein antibodies and their 57 infants (20 boys and 37 girls) diagnosed with cutaneous NLE (absent heart disease) between 1981 and 1997. At detection of the child's rash, 13 mothers were asymptomatic, 11 had an undifferentiated autoimmune syndrome (UAS), 9 had systemic lupus erythematosus (SLE), 7 Sjögren's syndrome (SS), 6 SLE/SS, and 1 rheumatoid arthritis/SS; 20 reported photosensitivity. Within 5 years, 7 asymptomatic mothers experienced disease progression: 1 developed photosensitivity, 2 SLE, 3 SS, 1 SLE/SS; in 2 mothers UAS progressed to SLE; and 2 mothers with SS developed SLE. The infant's rash often followed UV light exposure; mean age at detection was 6 weeks, and mean duration was 17 weeks. All had facial involvement (periorbital region most common) followed by the scalp, trunk, extremities, neck, and intertriginous areas. In 37, the rash resolved without sequelae, 43% of which were untreated. A quarter had residual sequelae that included telangiectasia and dyspigmentation. One child developed Hashimoto's thyroiditis, and 2 developed systemic-onset juvenile rheumatoid arthritis. Of 20 subsequent births, 7 children were healthy, 2 had congenital heart block (CHB) only, 4 CHB and skin rash, and 7 skin rash only. CONCLUSIONS Future pregnancies should be monitored by serial echocardiograms, given the substantial risk for heart block. Affected children should be observed for later development of a rheumatic disease.
Collapse
Affiliation(s)
- A R Neiman
- Department of Rheumatology and Medicine, Hospital for Joint Diseases, New York University School of Medicine, New York 10003, USA
| | | | | | | |
Collapse
|
39
|
Kim S, Li Q, Dang CV, Lee LA. Induction of ribosomal genes and hepatocyte hypertrophy by adenovirus-mediated expression of c-Myc in vivo. Proc Natl Acad Sci U S A 2000; 97:11198-202. [PMID: 11005843 PMCID: PMC17177 DOI: 10.1073/pnas.200372597] [Citation(s) in RCA: 146] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Overexpression of c-Myc in immortalized cells increases cell proliferation, inhibits cell differentiation, and promotes cell transformation. Recent evidence suggests that these effects, however, do not necessarily occur when c-Myc is overexpressed in primary mammalian cells. We sought to determine the immediate effects of transient overexpression of c-Myc in primary cells in vivo by using recombinant adenovirus to overexpress human MYC in mouse liver. Mice were intravenously injected with adenoviruses encoding MYC (Ad/Myc), E2F-1 (Ad/E2F-1), or beta-galactosidase (Ad/LacZ). Transgene expression was detectable 4 days after injection. Expression of ectopic c-Myc was immediately accompanied by enlarged and dysmorphic hepatocytes in the absence of significant cell proliferation or apoptosis. These findings were not present in the livers of mice injected with Ad/E2F-1 or Ad/LacZ. Prominent hepatocyte nuclei and nucleoli were associated with the up-regulation of large- and small-subunit ribosomal and nucleolar genes, suggesting that c-Myc may induce their expression to increase cell mass. Our studies support a role for c-Myc in the in vivo control of vertebrate cell size and metabolism independent of cell proliferation.
Collapse
Affiliation(s)
- S Kim
- Department of Medicine, and the Graduate Program of Molecular Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | | | | | | |
Collapse
|
40
|
Lee LA. Buzzwords with a basis. Nurs Manag (Harrow) 2000; 31:24-7; quiz 27-8. [PMID: 15127553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
Learn the essential elements that characterize the concepts of motivation, mentoring, and empowerment, and explore the integral relationships between and among the three.
Collapse
Affiliation(s)
- L A Lee
- Scott and White School of Nursing, University of Mary Hardin-Baylor, Belton, Tex., USA
| |
Collapse
|
41
|
|
42
|
Lee LA, Simon C, Bove EL, Mosca RS, Ebbini ES, Abrams GD, Ludomirsky A. High intensity focused ultrasound effect on cardiac tissues: potential for clinical application. Echocardiography 2000; 17:563-6. [PMID: 11000591 DOI: 10.1046/j.1540-8175.2000.00563.x] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
High intensity focused ultrasound (HIFU) is an evolving technology with potential therapeutic applications. Utilizing frequencies of 500 kHz to 10 MHz, HIFU causes localized hyperthermia at predictable depths without injuring intervening tissue. Applications in neurosurgery, urology, oncology and, more recently, cardiology for selective cardiac conduction tissue ablation have been promising. A 'noninvasive' technique for causing localized tissue damage to relieve hemodynamic and life-threatening obstruction in patients with congenital cardiac anomalies could replace more invasive procedures. We, therefore, investigated the ability of HIFU to create lesions in mammalian cardiac tissues ex vivo. Porcine valve leaflet, canine pericardium, human newborn atrial septum, and right atrial appendage were studied. Specimens were mounted and immersed in a water bath at room temperature. Using a 1-MHz phased array transducer, ultrasound energy was applied with an acoustic intensity of 1630 W/cm(2) or 2547 W/cm(2) until a visible defect was created (duration 3 to 25 sec). Macroscopic and microscopic examination demonstrated precise defects ranging from 3 to 4 mm in diameter. No damage was identified to the surrounding tissues. Our study concluded that HIFU can create precise defects in different cardiac tissue without damage to the surrounding tissue. Further investigation is needed to assess potential clinical uses of this technology.
Collapse
Affiliation(s)
- L A Lee
- Division of Pediatric Cardiology, Department of Pediatrics, University of Michigan, Ann Arbor, USA
| | | | | | | | | | | | | |
Collapse
|
43
|
Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, Xu Y, Wonsey D, Lee LA, Dang CV. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 2000; 275:21797-800. [PMID: 10823814 DOI: 10.1074/jbc.c000023200] [Citation(s) in RCA: 622] [Impact Index Per Article: 25.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Unlike normal mammalian cells, which use oxygen to generate energy, cancer cells rely on glycolysis for energy and are therefore less dependent on oxygen. We previously observed that the c-Myc oncogenic transcription factor regulates lactate dehydrogenase A and induces lactate overproduction. We, therefore, sought to determine whether c-Myc controls other genes regulating glucose metabolism. In Rat1a fibroblasts and murine livers overexpressing c-Myc, the mRNA levels of the glucose transporter GLUT1, phosphoglucose isomerase, phosphofructokinase, glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, and enolase were elevated. c-Myc directly transactivates genes encoding GLUT1, phosphofructokinase, and enolase and increases glucose uptake in Rat1 fibroblasts. Nuclear run-on studies confirmed that the GLUT1 transcriptional rate is elevated by c-Myc. Our findings suggest that overexpression of the c-Myc oncoprotein deregulates glycolysis through the activation of several components of the glucose metabolic pathway.
Collapse
Affiliation(s)
- R C Osthus
- Program in Human Genetics and Molecular Biology, Department of Medicine, and Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Koplin Winston F, Arbogast KB, Lee LA, Menon RA. Computer crash simulations in the development of child occupant safety policies. Arch Pediatr Adolesc Med 2000; 154:276-80. [PMID: 10710027 DOI: 10.1001/archpedi.154.3.276] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
OBJECTIVE To address the predictability of injury from air bag activation by use of crash simulation software. METHODS Using current, validated crash simulation software, the effect of air bag activation on injury risk was assessed for the 6-year-old child, both restrained and unrestrained. Results were compared with those for adult occupants in similar crash scenarios. RESULTS For the unrestrained child passenger, crash simulations predicted serious head, neck, and chest injuries with air bag activation, regardless of crash severity. For the restrained child passenger, crash simulations predicted similar severe injuries for high-severity crashes only. No serious injuries were predicted for unrestrained male adults exposed to air bags or for child passengers restrained in the rear seat for the crash scenarios simulated. CONCLUSIONS Using current crash simulation software, this study demonstrated that the risk of air bags to school-aged children could be predicted. Our results confirmed the previously identified risks to unrestrained children and provided the first evidence that air bags, in their current design, are not beneficial to restrained children. This study illustrates that computer crash simulations should be used proactively to identify injury risks to child occupants, particularly when limited real-world data are available.
Collapse
Affiliation(s)
- F Koplin Winston
- The Children's Hospital of Philadelphia and the University of Pennsylvania, USA.
| | | | | | | |
Collapse
|
45
|
Abraham SC, Cruz-Correa M, Lee LA, Yardley JH, Wu TT. Alendronate-associated esophageal injury: pathologic and endoscopic features. Mod Pathol 1999; 12:1152-7. [PMID: 10619269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
Ingestion of alendronate sodium (Fosamax) by osteoporotic patients can be associated with esophagitis and esophageal ulcer. Alendronate can damage the esophagus both by toxicity from the medication itself and by nonspecific irritation secondary to contact between the pill and the esophageal mucosa, similar to other cases of "pill esophagitis." Despite its wide use, the histologic appearances of alendronate-associated esophageal ulceration have not been previously described in detail, nor is this type of medication-induced injury commonly appreciated by pathologists when evaluating biopsies from ulcer sites. We report a series of 10 patients who experienced erosive/ulcerative esophagitis while ingesting alendronate, and describe the associated endoscopic and pathologic features. Biopsies from all patients showed inflammatory exudate and inflamed granulation tissue as characteristic of any ulcer site. Polarizable crystalline foreign material was present in six of 10 biopsies (60%). Multinucleated giant cells within the inflammatory exudate were present near this crystalline foreign material in three of 10 biopsies (30%). Adjacent squamous epithelium typically showed active inflammation and a reactive appearance with enlarged, hyperchromatic nuclei. Multinucleated squamous epithelial giant cells were present in two of 10 cases (20%). Microorganisms were unusual; scattered fungi and/or viral inclusions were present in only two of 10 biopsies (20%). Recognition of alendronate-associated erosive or ulcerative esophagitis, particularly in postmenopausal women, and communication of this possibility to the clinician can improve patient care.
Collapse
Affiliation(s)
- S C Abraham
- Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205-2196, USA.
| | | | | | | | | |
Collapse
|
46
|
Abstract
OBJECTIVE Aortic valve atresia or hypoplasia can present with a ventricular septal defect and a normal mitral valve and left ventricle. These patients may be suitable for biventricular repair, although the optimal initial management strategy remains unknown. METHODS From January 1991 through March 1999, 20 patients with aortic atresia or hypoplasia and ventricular septal defect underwent operation with the intent to achieve biventricular repair. Aortic atresia was present in 7 patients, and aortic valve hypoplasia was present in 13 patients. Among those patients with aortic hypoplasia, Z-scores of the aortic valve anulus ranged from -8.8 to -2.7. Associated anomalies included interrupted aortic arch (n = 12 patients), coarctation (n = 6 patients), aortopulmonary window (n = 1 patient), and heterotaxia (n = 1 patient). Nine patients were staged with an initial Norwood procedure followed by biventricular repair in 8 patients. One patient awaits biventricular repair after a Norwood procedure. The conditions of 11 patients were corrected with a single procedure. RESULTS Among the 9 patients who underwent staged repair, there were no deaths after the Norwood procedure and 1 death after biventricular repair. For the 11 patients who underwent a primary biventricular repair, there was 1 early death and 2 late deaths from noncardiac causes. Follow-up ranged from 1 to 85 months (mean, 28 months). Actuarial survival for the entire group was 78% +/- 10% at 5 years and was not significantly different between staged repair (89%) and primary biventricular repair (73%). CONCLUSIONS Both primary and staged biventricular repair for patients with aortic atresia or hypoplasia and ventricular septal defect may be performed with good late survival. Refinements in technique of conduit insertion and arch reconstruction have resulted in primary biventricular repair becoming our preferred approach.
Collapse
Affiliation(s)
- R G Ohye
- Division of Pediatric Cardiovascular Surgery, Section of Cardiac Surgery, C.S. Mott Children's Hospital, University of Michigan School of Medicine, Ann Arbor, USA
| | | | | | | | | | | |
Collapse
|
47
|
Abstract
Ultraviolet radiation plays an important role in the induction of lesions in many patients with cutaneous lupus. In the photosensitive subset of lupus, subacute cutaneous lupus, the effects of ultraviolet radiation likely act in concert with specific autoantibodies, particularly anti-Ro-related autoantibodies, to produce lesions. Potential effects of ultraviolet radiation on the induction of cutaneous lupus, and the potential interplay of specific autoantibodies with ultraviolet radiation are discussed. The steps involved in the induction of cutaneous lupus lesions by ultraviolet radiation have not been fully elucidated. Recent advances in phototesting and analysis of the genetics of lupus should clarify the events leading to photosensitive cutaneous lupus lesions.
Collapse
Affiliation(s)
- L A Lee
- Department of Medicine, Denver Health Medical Center, Colorado, USA.
| | | |
Collapse
|
48
|
Lee LA, Walsh P, Prater CA, Su LJ, Marchbank A, Egbert TB, Dellavalle RP, Targoff IN, Kaufman KM, Chorzelski TP, Jablonska S. Characterization of an autoantigen associated with chronic ulcerative stomatitis: the CUSP autoantigen is a member of the p53 family. J Invest Dermatol 1999; 113:146-51. [PMID: 10469295 DOI: 10.1046/j.1523-1747.1999.00651.x] [Citation(s) in RCA: 48] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
A unique clinical syndrome has been described in which patients have chronic oral ulceration and autoantibodies to nuclei of stratified squamous epithelium. We have characterized the autoantibodies from patients sera and found that the major autoantigen is a 70 kDa epithelial nuclear protein. Sequencing of the cDNA for this protein, chronic ulcerative stomatitis protein, revealed it to be homologous to the p53 tumor suppressor and to the p73 putative tumor suppressor, and to be a splicing variant of the KET gene. The p53-like genes, p73 and the several KET splicing variants, are recently described genes of uncertain biologic and pathologic significance. This study provides the first clear association of a p53-like protein with a disease process.
Collapse
Affiliation(s)
- L A Lee
- Department of Medicine, Denver Health Medical Center, Colorado, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Abstract
PURPOSE In order to understand and update the prevalence of myopia in Taiwan, a nationwide survey was performed in 1995. METHODS We stratified the cluster sampling by developmental grading of the city, using a size proportional to the population. Two cities were randomly selected from each city grading. The total number of students enrolled was 11,178, including 5,676 boys and 5,502 girls. The refractive status and corneal radius of each student were measured with an autorefractometer under cycloplegia and checked with retinoscopy. Axial length was measured with biometric ultrasound. RESULTS The myopic rate was from 12% at the age of 6, it increased to 56% at the age of 12, and then to 76% at the age of 15. A myopic rate of 84% was found for the age range of 16 to 18. The prevalence of high myopia (over -6.0 D) at the age of 18 was 20% in girls and 12% in boys. The mean refractive status became myopic at the age of 9, then increased to -3.92 D in girls and -2.71 D in boys at the age of 18. The increase of axial length is correspondent with the progression of myopia. The anterior chamber depth (ACD) was deeper with age and the severity of myopia, whereas the corneal curvature remained unchanged. The lens thickness became thinner from age 7 to 13, then it became thicker with age and the severity of myopia after age 15. The prevalence and degree of myopia in girls was more severe than in boys. CONCLUSIONS The prevalence of myopia in Taiwan increased year by year. The increase in severity and prevalence of high myopia may be due to earlier onset.
Collapse
Affiliation(s)
- L L Lin
- Department of Ophthalmology, College of Medicine, National Taiwan University, Taipei
| | | | | | | | | | | | | |
Collapse
|
50
|
Abstract
BACKGROUND Cutaneous neonatal lupus erythematosus (NLE) is an uncommon disease described mainly through isolated case reports. OBJECTIVE Our purpose was to examine the cutaneous spectrum, clinical associations, and course of disease in babies with anti-Ro-positive NLE. METHODS This is a retrospective case series evaluation of newborns with anti-Ro-positive NLE seen at a single ambulatory care university center over a 20-year period. Cases were drawn from a population of 3.2 million. Follow-up was at least 3 years. RESULTS Four boys and 14 girls were included in our evaluation. Distribution of skin lesions in 18 babies was as follows: face, 17; periorbital "owl-eye" or "eye mask" facial rash, 14; scalp, 15; arms and legs, 13; trunk and groin, 6. Crusted lesions were predominant in 3. Photosensitivity was seen in 12, and features of cutis marmorata telangiectasia congenita were observed in 4. In 17 neonatal lupus was not suspected until the dermatology consultation. Noncutaneous manifestations included thrombocytopenia in 4, cholestatic hepatitis in 3, and congenital heart block in 3. Four patients had residual telangiectasia that persisted for 3 or more years but eventually cleared in 2 patients. Three babies had dyspigmentation that spontaneously cleared within 22 months. None had atrophy or scarring. CONCLUSION Periorbital, scalp, and extremity lesions are common in cutaneous NLE. Crusted lesions predominated in male infants. In children selected by cutaneous involvement, thrombocytopenia and hepatic disease were present as frequently as cardiac disease and occurred more frequently in male babies with crusted skin lesions. Children with cutaneous NLE should be evaluated for hematologic and hepatic as well as cardiac involvement.
Collapse
Affiliation(s)
- W L Weston
- Department of Dermatology, University of Colorado School of Medicine, Denver Health Medical Center, USA
| | | | | |
Collapse
|